REVIVA PHARMA HLDGS INC by Reviva Pharmaceuticals Holdings, Inc. (RVPH) Stock Price Target 2026

The average analyst price target for REVIVA PHARMA HLDGS INC by Reviva Pharmaceuticals Holdings, Inc. is $123.44, 34188.9% above the current price. Of 8 analysts, 6 rate it Buy and 2 Hold. Targets range from $1 to $340. The latest change came on Apr 8, 2026, when Maxim Group downgraded REVIVA PHARMA HLDGS INC by Reviva Pharmaceuticals Holdings, Inc. from Buy to Hold.

The Average Analyst Price Target for REVIVA PHARMA HLDGS INC by Reviva Pharmaceuticals Holdings, Inc. is $123.44.

Price Target Range — 10 Quarters

Analyst Consensus — 8 Analysts

6Buy

2Hold

Consensus RatingBuy# Analysts8Avg. Consensus PT$123.44Upside to Avg. PT+34188.9%

Rating Trend — Last 9 Months

Latest Upgrades and Downgrades for REVIVA PHARMA HLDGS INC by Reviva Pharmaceuticals Holdings, Inc. Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Apr 8, 2026	Maxim Group	Jason McCarthy	Downgrade	Buy→Hold	—
Mar 31, 2026	Roth Capital	Boobalan Pachaiyappan	PT Cut	Buy	$2→$1
Mar 30, 2026	Alliance Global Partners	James Molloy	PT Raise	Buy	$16→$30
Mar 5, 2026	D. Boral Capital	Jason Kolbert	Downgrade	Buy→Hold	—
Jan 5, 2026	Chardan Capital	Keay Nakae	Maintained	Buy	$40
Dec 23, 2025	D. Boral Capital	Jason Kolbert	Maintained	Buy	$40
Dec 23, 2025	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$80
Nov 19, 2025	D. Boral Capital	Jason Kolbert	Maintained	Buy	$40
Oct 28, 2025	D. Boral Capital	Jason Kolbert	Maintained	Buy	$40
Oct 27, 2025	HC Wainwright & Co.	Raghuram Selvaraju	PT Cut	Buy	$220→$80
Sep 29, 2025	Chardan Capital	Rudy Li	Initiate	Buy	$40
Sep 19, 2025	D. Boral Capital	Jason Kolbert	PT Cut	Buy	$60→$40
Sep 15, 2025	Benchmark	Bruce D. Jackson	PT Cut	Speculative Buy	$280→$140
Aug 18, 2025	Roth Capital	Boobalan Pachaiyappan	PT Cut	Buy	$140→$60
Aug 18, 2025	D. Boral Capital	Jason Kolbert	Maintained	Buy	$60
Aug 15, 2025	Maxim Group	Jason McCarthy	PT Cut	Buy	$100→$40
Jun 27, 2025	D. Boral Capital	Jason Kolbert	Maintained	Buy	$60
Jun 3, 2025	D. Boral Capital	Jason Kolbert	Maintained	Buy	$60
May 20, 2025	D. Boral Capital	Jason Kolbert	PT Cut	Buy	$160→$60
Apr 24, 2025	D. Boral Capital	Jason Kolbert	Maintained	Buy	$160

Analyst Ratings News

PRO
Maxim Group Downgrades Reviva Pharmaceuticals to Hold

Maxim Group analyst Jason McCarthy downgrades Reviva Pharmaceuticals (NASDAQ:RVPH) from Buy to Hold.

Benzinga Newsdesk

PRO
Watching Reviva Pharmaceuticals; Zacks Small-Cap Research Gives Stock $7 Price Valuation

Benzinga Newsdesk

PRO
D. Boral Capital Downgrades Reviva Pharmaceuticals to Hold

D. Boral Capital analyst Jason Kolbert downgrades Reviva Pharmaceuticals (NASDAQ:RVPH) from Buy to Hold.

Benzinga Newsdesk

PRO
D. Boral Capital Maintains Buy on Reviva Pharmaceuticals, Maintains $2 Price Target

D. Boral Capital analyst Jason Kolbert maintains Reviva Pharmaceuticals (NASDAQ:RVPH) with a Buy and maintains $2 price target.

Benzinga Newsdesk

PRO
D. Boral Capital Maintains Buy on Reviva Pharmaceuticals, Maintains $2 Price Target

D. Boral Capital analyst Jason Kolbert maintains Reviva Pharmaceuticals (NASDAQ:RVPH) with a Buy and maintains $2 price target.

Benzinga Newsdesk

PRO
D. Boral Capital Maintains Buy on Reviva Pharmaceuticals, Maintains $2 Price Target

D. Boral Capital analyst Jason Kolbert maintains Reviva Pharmaceuticals (NASDAQ:RVPH) with a Buy and maintains $2 price target.

Benzinga Newsdesk